Influenza vaccination and prevention of antimicrobial resistance

Abuse and misuse of available antimicrobial drugs have increased antimicrobial resistance (AMR), with relevant adverse health and economic impacts. Several factors suggest that the influenza vaccine is a possible effective measure to control AMR through a significant reduction in antibiotic consumpt...

Full description

Saved in:
Bibliographic Details
Published inExpert review of vaccines Vol. 17; no. 10; pp. 881 - 888
Main Authors Esposito, Susanna, Principi, Nicola
Format Journal Article
LanguageEnglish
Published England Taylor & Francis Group 03.10.2018
Subjects
Online AccessGet full text
ISSN1476-0584
1744-8395
DOI10.1080/14760584.2018.1525298

Cover

Loading…
Abstract Abuse and misuse of available antimicrobial drugs have increased antimicrobial resistance (AMR), with relevant adverse health and economic impacts. Several factors suggest that the influenza vaccine is a possible effective measure to control AMR through a significant reduction in antibiotic consumption. In this paper, aspects related will be discussed. Areas covered: Although the effectiveness of influenza immunization can significantly vary according to the study design, the circulating influenza viruses, the type of vaccine, the age of the enrolled subjects, the outcome measured and the season of the study, all experts agree that the influenza vaccine can significantly reduce the risk of contracting influenza in subjects of any age. Consequently, influenza vaccination may reduce the number of bacterial superimposed infections that can complicate influenza and require antibiotic prescriptions. Expert commentary: Several indirect and direct observations seem to indicate that influenza vaccines can play an important role in reducing influenza-related antibiotic prescriptions. This finding can lead to at least two undeniable advantages, reductions in drug expenditure and limitations of the risk of favoring AMR development. However, only when universal vaccination is accepted and implemented will the true advantages of the influenza vaccine in reducing AMR development be completely known and exploited.
AbstractList Introduction: Abuse and misuse of available antimicrobial drugs have increased antimicrobial resistance (AMR), with relevant adverse health and economic impacts. Several factors suggest that the influenza vaccine is a possible effective measure to control AMR through a significant reduction in antibiotic consumption. In this paper, aspects related will be discussed. Areas covered: Although the effectiveness of influenza immunization can significantly vary according to the study design, the circulating influenza viruses, the type of vaccine, the age of the enrolled subjects, the outcome measured and the season of the study, all experts agree that the influenza vaccine can significantly reduce the risk of contracting influenza in subjects of any age. Consequently, influenza vaccination may reduce the number of bacterial superimposed infections that can complicate influenza and require antibiotic prescriptions. Expert commentary: Several indirect and direct observations seem to indicate that influenza vaccines can play an important role in reducing influenza-related antibiotic prescriptions. This finding can lead to at least two undeniable advantages, reductions in drug expenditure and limitations of the risk of favoring AMR development. However, only when universal vaccination is accepted and implemented will the true advantages of the influenza vaccine in reducing AMR development be completely known and exploited.
Abuse and misuse of available antimicrobial drugs have increased antimicrobial resistance (AMR), with relevant adverse health and economic impacts. Several factors suggest that the influenza vaccine is a possible effective measure to control AMR through a significant reduction in antibiotic consumption. In this paper, aspects related will be discussed. Areas covered: Although the effectiveness of influenza immunization can significantly vary according to the study design, the circulating influenza viruses, the type of vaccine, the age of the enrolled subjects, the outcome measured and the season of the study, all experts agree that the influenza vaccine can significantly reduce the risk of contracting influenza in subjects of any age. Consequently, influenza vaccination may reduce the number of bacterial superimposed infections that can complicate influenza and require antibiotic prescriptions. Expert commentary: Several indirect and direct observations seem to indicate that influenza vaccines can play an important role in reducing influenza-related antibiotic prescriptions. This finding can lead to at least two undeniable advantages, reductions in drug expenditure and limitations of the risk of favoring AMR development. However, only when universal vaccination is accepted and implemented will the true advantages of the influenza vaccine in reducing AMR development be completely known and exploited.
Author Esposito, Susanna
Principi, Nicola
Author_xml – sequence: 1
  givenname: Susanna
  surname: Esposito
  fullname: Esposito, Susanna
  organization: a Pediatric Clinic, Department of Surgical and Biomedical Sciences , Università degli Studi di Perugia , Perugia , Italy
– sequence: 2
  givenname: Nicola
  surname: Principi
  fullname: Principi, Nicola
  organization: b Università degli Studi di Milano , Milan , Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30259755$$D View this record in MEDLINE/PubMed
BookMark eNo9kMtOwzAQRS1UREvhE0D5gRTb8cT2DlTxqFSJDayjsT1BrlKnStJK8PWEFljNnaOrs7iXbJLaRIzdCL4Q3PA7oXTJwaiF5MIsBEiQ1pyxmdBK5aawMBnz2Ml_SlN22fcbzgtlQV-wacElWA0wY_erVDd7Sl-YHdD7mHCIbcowhWzX0YHS8W3rkQxxG33XuohN1lEf-wGTpyt2XmPT0_XvnbP3p8e35Uu-fn1eLR_WuVeFHHInUZbCC4WcUApnuXSGSstBlFBaNKAtggNPKmgvCtLow4hdrURZC13M2erkDS1uql0Xt9h9Vi3G6gja7qPCboi-oUqrQKHkyhIHpdxosahEQIfjTB7M6Lo9uXZ7t6Xwb_ubpfgGO5ZnNw
CitedBy_id crossref_primary_10_1093_cid_ciaa464
crossref_primary_10_1016_j_eujim_2020_101111
crossref_primary_10_1093_cid_ciz1244
crossref_primary_10_12688_f1000research_75869_2
crossref_primary_10_1007_s40121_020_00312_7
crossref_primary_10_1093_cid_ciad562
crossref_primary_10_3390_vaccines7040168
crossref_primary_10_1109_ACCESS_2021_3082108
crossref_primary_10_3390_vaccines12040384
crossref_primary_10_3390_children8090782
crossref_primary_10_3390_antibiotics12010138
crossref_primary_10_1080_14740338_2019_1640678
crossref_primary_10_1186_s13756_022_01173_0
crossref_primary_10_3923_jms_2021_1_8
crossref_primary_10_1080_21645515_2022_2151291
crossref_primary_10_1080_21645515_2023_2300848
crossref_primary_10_1093_cid_ciaa1221
crossref_primary_10_3389_fimmu_2018_02700
crossref_primary_10_1080_21645515_2019_1633877
crossref_primary_10_1016_j_jval_2020_09_005
crossref_primary_10_3390_vaccines10040554
crossref_primary_10_12688_f1000research_75869_1
crossref_primary_10_1093_jac_dkad340
ContentType Journal Article
CorporateAuthor European Society of Clinical Microbiology Infectious Diseases (ESCMID) Vaccine Study Group (EVASG)
CorporateAuthor_xml – name: European Society of Clinical Microbiology Infectious Diseases (ESCMID) Vaccine Study Group (EVASG)
DBID NPM
DOA
DOI 10.1080/14760584.2018.1525298
DatabaseName PubMed
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
DatabaseTitleList
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1744-8395
EndPage 888
ExternalDocumentID oai_doaj_org_article_74ded6049e0544b9a89a41daba152c58
30259755
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
0VX
0YH
29G
4.4
53G
5GY
7X7
88E
8AO
8C1
8FI
8FJ
AAGSP
AAHJP
AANCX
AAOUU
ABEIZ
ABJNI
ABJXJ
ABKMU
ABLKL
ABUWG
ABXYU
ACFRI
ACGFS
ADBBV
ADCVX
ADTKB
AECIN
AENEX
AEOZL
AESAV
AFKRA
AFRVT
AGDLA
AGMLL
AHMBA
AIJEM
AIYSM
AKBVH
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AN0
BENPR
BLEHA
BNQBC
BPHCQ
BVXVI
CBZEQ
CCCUG
CCPQU
CS3
DDEWX
DGYZD
DU5
EBS
EJD
F5P
FYUFA
GROUPED_DOAJ
H13
HMCUK
HZ~
IAO
IEA
IHR
ITC
KYCEM
LJTGL
M1P
M4Z
MV1
NPM
O9-
OVD
P2P
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
RNANH
SJN
TBQAZ
TCNNB
TDBHL
TEORI
TFL
TFW
TUROJ
UKHRP
ID FETCH-LOGICAL-c432t-b2a261c14a0ea21b902b8e690516569a8579a5b5ce4d7c13e7acd9a8bf416f173
IEDL.DBID DOA
ISSN 1476-0584
IngestDate Wed Aug 27 01:28:06 EDT 2025
Mon Jul 21 06:06:25 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords influenza
Antibiotics
antimicrobial resistance
influenza viruses
influenza vaccination
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c432t-b2a261c14a0ea21b902b8e690516569a8579a5b5ce4d7c13e7acd9a8bf416f173
OpenAccessLink https://doaj.org/article/74ded6049e0544b9a89a41daba152c58
PMID 30259755
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_74ded6049e0544b9a89a41daba152c58
pubmed_primary_30259755
PublicationCentury 2000
PublicationDate 2018-10-03
PublicationDateYYYYMMDD 2018-10-03
PublicationDate_xml – month: 10
  year: 2018
  text: 2018-10-03
  day: 03
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Expert review of vaccines
PublicationTitleAlternate Expert Rev Vaccines
PublicationYear 2018
Publisher Taylor & Francis Group
Publisher_xml – name: Taylor & Francis Group
SSID ssj0034957
Score 2.3163571
SecondaryResourceType review_article
Snippet Abuse and misuse of available antimicrobial drugs have increased antimicrobial resistance (AMR), with relevant adverse health and economic impacts. Several...
Introduction: Abuse and misuse of available antimicrobial drugs have increased antimicrobial resistance (AMR), with relevant adverse health and economic...
SourceID doaj
pubmed
SourceType Open Website
Index Database
StartPage 881
SubjectTerms antibiotics
antimicrobial resistance
influenza
influenza vaccination
influenza viruses
Title Influenza vaccination and prevention of antimicrobial resistance
URI https://www.ncbi.nlm.nih.gov/pubmed/30259755
https://doaj.org/article/74ded6049e0544b9a89a41daba152c58
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEF6kIHgR39YXOXgNbbKv7M0Hliq0eLDQW5h9QQ-mRWJBf72zu6mIFy9eAhnCEGbYzDdh5vsIuS68Yl7hAQRd-pxB6XLFqMk92imA9SIu0k6mYjxjT3M-_yH1FWbCEj1wCtxAMuusQBzrEFwwraBSwAoLGrDyGB7XfLHmbZqp9A2mCPujrAqT2C9jjd3s7lTDQbAFUxjrqqL8T6mqjrH_F7aMNWa0R3Y7cJjdppfaJ1uuOSDbSS7y45DcPCZFkU_I1mDMIv3Iy6Cx2apjYsLbpUdLu3hdRIoldIcNdQCJmN0jMhs9vNyP804BITeMlm2uS8AOxxQMhg7KQqthqSsnAqcW4jCMBZcKuObGMStNQZ0EY9GsPeIsX0h6THrNsnGnJBMUHMIJYTgY5rAr1Fbj2RQan0eMZ_vkLkSgXiWSizrQTkcDJqPuklH_lYw-OUnx-3ZDEVMpyfnZf7g_JzshaXGWjl6QXvv27i4RE7T6KqYfr9PnyRcCtLL2
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influenza+vaccination+and+prevention+of+antimicrobial+resistance&rft.jtitle=Expert+review+of+vaccines&rft.au=Susanna+Esposito&rft.au=Nicola+Principi&rft.date=2018-10-03&rft.pub=Taylor+%26+Francis+Group&rft.issn=1476-0584&rft.eissn=1744-8395&rft.volume=17&rft.issue=10&rft.spage=881&rft.epage=888&rft_id=info:doi/10.1080%2F14760584.2018.1525298&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_74ded6049e0544b9a89a41daba152c58
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-0584&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-0584&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-0584&client=summon